{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-009476","form_type":"8-K","ticker":"MDGL","cik":"0001157601","company_name":"MADRIGAL PHARMACEUTICALS, INC.","filed_at":"2026-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.623164+00:00","generated_at":"2026-05-16T01:39:32.743818+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Madrigal reports Q4 Rezdiffra sales $321M, FY $958M; pipeline expands with siRNA and GLP-1 deals","bullets":["Q4 2025 Rezdiffra net sales $321.1M; full-year net sales $958.4M, vs $180.1M in 2024.","More than 36,250 patients on Rezdiffra as of year-end 2025.","Cash, equivalents and marketable securities $988.6M as of Dec. 31, 2025.","Licensed global rights to six pre-clinical siRNA programs and oral GLP-1 (MGL-2086) to combine with Rezdiffra.","Secured Orange Book listed Rezdiffra patent with protection into 2045; also closed $500M credit facility."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-009476","json":"https://secwatch.observer/filing/0001628280-26-009476.json","markdown":"https://secwatch.observer/filing/0001628280-26-009476.md","text":"https://secwatch.observer/filing/0001628280-26-009476.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026009476/0001628280-26-009476-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026009476/mdgl-20260219.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:39:32.743818+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}